JMP Securities maintains Solid Biosciences stock with $15 target

On Wednesday, JMP Securities reiterated their Market Outperform rating on Solid Biosciences (NASDAQ:SLDB) with a steady price target of $15.00. Currently trading at $3.04, the company has a market capitalization of $121.5 million. According to InvestingPro data, analyst consensus remains bullish, with price targets ranging from $12 to $28. The firm’s analysts highlighted the company’s progress in its INSPIRE DUCHENNE trial, which is evaluating SGT-003, a gene therapy for Duchenne Muscular Dystrophy (DMD). Solid Biosciences is expected to release initial safety, expression, and 90-day biomarker data from the trial within the first quarter of 2025. InvestingPro analysis shows the company maintains a strong liquidity position with a current ratio of 7.85, though it’s currently burning through cash rapidly.

The forthcoming data will cover outcomes from three patients who have been monitored over a three-month period. JMP Securities anticipates that the interim readout will confirm SGT-003’s tolerability and will identify the expression levels of microdystrophin in muscle tissue. Microdystrophin expression is considered crucial for accelerated approval in DMD gene therapy.

Additionally, the analysts are looking to see how the presence of microdystrophin correlates with changes in the physical function of patients, even at this early stage of the trial. The trial’s results are keenly awaited as they will provide insights into the therapy’s potential efficacy and safety profile.

The INSPIRE DUCHENNE trial is a significant part of Solid Biosciences’ efforts to develop a treatment for DMD, a genetic disorder characterized by progressive muscle degeneration and weakness. The company’s focus on delivering meaningful data is a critical step towards potentially offering a new therapy for those affected by this condition.

Solid Biosciences’ stock performance will likely be influenced by the outcomes of the trial as investors and stakeholders closely monitor the developments in the company’s gene therapy research. The stock has experienced significant volatility, currently trading near its 52-week low of $2.92, representing a 60.8% decline over the past six months. InvestingPro subscribers have access to 12 additional key insights about Solid Biosciences, including detailed financial health metrics and comprehensive valuation analysis through the Pro Research Report, available for over 1,400 US stocks.

In other recent news, Solid Biosciences has been making significant strides in the field of gene therapy. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s gene therapy candidate SGT-212 for the treatment of Friedreich’s ataxia (FA), a serious genetic neurodegenerative disease. This follows the FDA’s previous Investigational New Drug (IND) clearance for SGT-212.

Moreover, Solid Biosciences has secured exclusive worldwide licenses to Mayo Clinic’s Suppression-Replacement gene therapy platform and several cardiac gene therapy programs. This collaboration aims to develop gene therapies targeting genetic cardiac conditions that can lead to sudden death.

On the analyst front, Truist Securities and JMP Securities have initiated coverage on Solid Biosciences with a Buy and Market Outperform rating respectively, setting price targets of $16.00 and $15.00. Truist Securities sees potential upside with the ongoing Phase 1/2 study of SGT-003 in Duchenne muscular dystrophy, while JMP Securities appreciates the company’s expertise in transgene optimization and advanced capsids.

These developments underscore Solid Biosciences’ commitment to advancing gene therapy and addressing unmet medical needs in neuromuscular and cardiac diseases.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.